Pharmadel LLC's Kingskin Salicylic Acid Recall Signals cGMP Compliance Gaps for OTC Market
Pharmadel LLC initiated a Class II recall (D-0381-2025) for 20,048 bottles of Kingskin (Salicylic Acid) due to cGMP deviations from its New Castle, DE facility. This event, terminated on January 8, 2026, highlights critical compliance risks for procurement and regulatory teams sourcing OTC topical drugs. Businesses must reassess supplier due diligence and ensure robust quality agreements to mitigate supply chain disruptions from similar regulatory actions.
FDA Class II Recall: cGMP Deviations Trigger Pharmadel LLC's Kingskin Withdrawal
On April 15, 2025, Pharmadel LLC initiated a voluntary Class II recall, designated D-0381-2025, for 20,048 bottles of its Kingskin product. This topical human over-the-counter (OTC) drug, formulated with Salicylic Acid (UNII: O414PZ4LPZ) and marketed for common wart removal, was distributed under NDC 55758-409-15. The primary reason cited for this significant market action was cGMP (current Good Manufacturing Practice) deviations. For procurement directors, this recall underscores the critical importance of rigorous supplier qualification and ongoing oversight, particularly for OTC drug manufacturers. A Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This scenario demands immediate review of existing quality agreements and audit schedules for any suppliers of similar topical Salicylic Acid formulations, ensuring their adherence to FDA cGMP standards to prevent similar disruptions to your supply chain. The affected lots, KSE-01 (EXP: OCT 26) and KSE-02 (EXP: FEB 27), highlight that the manufacturing deficiencies had implications for products with extended shelf lives, necessitating a comprehensive review of quality control processes.
Operational Impact at Pharmadel LLC's Historic New Castle, Delaware Facility
The recall of Kingskin directly implicates Pharmadel LLC's manufacturing and distribution operations located at 650 Centerpoint Blvd, Historic New Castle, DE 19720-8108. The cGMP deviations originating from this facility mean that the processes, procedures, or controls in place for producing the Salicylic Acid topical drug were deemed inadequate by the firm, leading to the voluntary recall. For supply chain VPs, this event necessitates a deeper dive into the operational integrity of any third-party manufacturers located within the United States, even those with seemingly localized distribution patterns like Pharmadel's initial reported distribution limited to Delaware. The incident serves as a reminder that geographical proximity does not inherently guarantee compliance. Businesses relying on contract manufacturing organizations (CMOs) for OTC products must ensure their quality systems are robust enough to detect and correct cGMP non-conformities before they escalate into market withdrawals, impacting product availability and brand reputation. Proactive auditing and transparent communication channels with manufacturing partners are essential to mitigate risks associated with facility-specific compliance failures.
Supply Chain Implications for Topical Salicylic Acid Procurement
While the immediate distribution pattern for Pharmadel LLC's Kingskin was reported as limited to Delaware, the underlying cGMP deviations have broader implications for the global procurement of Salicylic Acid and other topical OTC drug components. Regulatory affairs heads must recognize that a recall due to cGMP issues, regardless of initial distribution scope, signals a potential systemic vulnerability in manufacturing quality control. For companies sourcing Salicylic Acid (HSN 2918.21) or finished topical medicaments (HSN 3004.90), this event should trigger a re-evaluation of supplier risk profiles. The commercial impact extends beyond the recalled product itself, potentially affecting market confidence in other topical Salicylic Acid products from less scrutinized manufacturers. Business development executives should consider how such incidents influence consumer trust and market demand for compliant, high-quality alternatives. Ensuring a diversified supplier base with thoroughly vetted quality management systems is paramount to insulate operations from localized manufacturing failures and maintain uninterrupted product supply to consumers.
Ensuring Continuity: Alternative Salicylic Acid Suppliers and Qualification
For procurement directors seeking to mitigate risks associated with events like the Pharmadel LLC recall, identifying and qualifying alternative suppliers for Salicylic Acid is a strategic imperative. While ChemLifeIntel's knowledge graph does not specifically name alternative suppliers for Pharmadel LLC's Kingskin, Salicylic Acid is a widely available active pharmaceutical ingredient (API) used in numerous dermatological and OTC preparations. Companies should initiate or accelerate processes to identify manufacturers with robust cGMP compliance records, potentially including firms in diverse geographies to enhance supply chain resilience. The qualification timeline for a new API or finished product supplier can range from 6 to 18 months, encompassing audits, analytical testing, stability studies, and regulatory filings. Therefore, proactive identification and engagement with potential alternatives are crucial. This event reinforces the need for a multi-source strategy to prevent single-point-of-failure scenarios, ensuring continuous availability of critical OTC products and safeguarding market share against unforeseen regulatory actions.
Pharmadel LLC's Regulatory Compliance Record and Industry Context
ChemLifeIntel's knowledge graph does not provide a history of prior FDA Warning Letters, 483 observations, or Import Alerts specifically for Pharmadel LLC. This current Class II recall due to cGMP deviations therefore represents a significant regulatory event for the company. For regulatory affairs heads, the absence of publicly available prior enforcement actions does not diminish the severity of the current recall, as cGMP non-compliance can lead to escalating regulatory scrutiny. It is imperative for Pharmadel LLC to demonstrate comprehensive corrective and preventive actions (CAPA) to the FDA to address the root causes of these deviations. In the broader industry context, recent parallel events, such as Essential Wellness Pharma's Class II recall for sterility failures in Progesterone Injection (June 2026) and the FDA hearing concerning Amgen's Tavneos (June 2026), underscore a heightened regulatory environment across the pharmaceutical sector. While these are unrelated to Pharmadel LLC, they illustrate the FDA's persistent focus on manufacturing quality and product safety, signaling that all firms, regardless of size or product type, face rigorous oversight.
Recall Termination and Future Compliance Outlook for Pharmadel LLC
The FDA officially terminated the recall D-0381-2025 for Pharmadel LLC's Kingskin on January 8, 2026. Recall termination signifies that the firm has completed all necessary actions to remove or correct the recalled product from the market, and the FDA is satisfied that the recall strategy has been effectively implemented. However, for business development executives and regulatory affairs teams, termination does not imply that the underlying cGMP deviations have been fully resolved to the FDA's satisfaction for future manufacturing. Pharmadel LLC remains obligated to implement robust corrective and preventive actions (CAPA) to address the root causes of the cGMP failures that led to this recall. Failure to adequately remediate these issues could result in future regulatory actions, including potential Warning Letters, product seizure, or even injunctions. Companies engaging with Pharmadel LLC, whether as customers or partners, should seek assurances regarding the comprehensive nature of their CAPA plans and monitor any subsequent FDA inspections or communications to gauge the company's long-term compliance trajectory and mitigate future supply chain risks.